Contributions
Abstract: EP1323
Type: ePoster
Abstract Category: Clinical aspects of MS - 4 Natural course
Cerebrospinal fluid (CSF) immunoglobulin free light chains (FLCs) have been suggested to provide prognostic information in clinically isolated syndrome (CIS). The objective of this study was to assess the prognostic value of FLCs in patients with CIS suggestive of multiple sclerosis (MS) in a group of patients from Buenos Aires, Argentina.
Methods: Paired CSF and serum samples from 36 patients presenting with CIS were collected between 2014 and 2017. CSF and serum kappa (K) and lambda (L) FLC concentrations were measured using the FLC immunoassay Freelite™(The Binding Site, Birmingham, UK) on a SPAPLUS analyzer. Demographic and clinical data was recorded, and mainly included time between CIS diagnosis and conversion, and the degree of disability (determined by the EDSS scale). MRI at baseline and follow-up (every 12 months) was evaluated to determine the percent brain volume change (PBVC) as a measure of brain atrophy. FLC concentrations were compared in CIS-MS converters vs. CIS non-converters and expressed as median±SD and the correlation between FLC and PBVC was assessed by binary logistic and Cox regression analyses.
Results: A total of 36 patients were included, median age 37±4 years, median follow-up time 28 ±9 months, during which 22 (61.1 %) patients converted to MS. The median concentration of FLCs at CIS diagnosis was slightly higher in CIS-converters compared to non-converters, but this did not reach statistical significance (KFLC: 7±5.3 mg/L vs. 5±2.3 mg/L, p= 0.11; LFLC: 0.7±0.33 mg/L vs. 0.5±0.23 mg/L p=0.16). A strong inverse correlation was observed between the concentration of K and LFLCs at diagnosis and the change in PBVC during follow-up (r= - 0.72 and r= - 0.65, respectively).
Conclusion: FLC concentrations at CIS diagnosis were not significantly higher in CIS-converters compared to CIS non-converters, but patients with higher CSF FLC concentrations tended to have increased brain atrophy during follow-up.
Disclosure: No funding
Abstract: EP1323
Type: ePoster
Abstract Category: Clinical aspects of MS - 4 Natural course
Cerebrospinal fluid (CSF) immunoglobulin free light chains (FLCs) have been suggested to provide prognostic information in clinically isolated syndrome (CIS). The objective of this study was to assess the prognostic value of FLCs in patients with CIS suggestive of multiple sclerosis (MS) in a group of patients from Buenos Aires, Argentina.
Methods: Paired CSF and serum samples from 36 patients presenting with CIS were collected between 2014 and 2017. CSF and serum kappa (K) and lambda (L) FLC concentrations were measured using the FLC immunoassay Freelite™(The Binding Site, Birmingham, UK) on a SPAPLUS analyzer. Demographic and clinical data was recorded, and mainly included time between CIS diagnosis and conversion, and the degree of disability (determined by the EDSS scale). MRI at baseline and follow-up (every 12 months) was evaluated to determine the percent brain volume change (PBVC) as a measure of brain atrophy. FLC concentrations were compared in CIS-MS converters vs. CIS non-converters and expressed as median±SD and the correlation between FLC and PBVC was assessed by binary logistic and Cox regression analyses.
Results: A total of 36 patients were included, median age 37±4 years, median follow-up time 28 ±9 months, during which 22 (61.1 %) patients converted to MS. The median concentration of FLCs at CIS diagnosis was slightly higher in CIS-converters compared to non-converters, but this did not reach statistical significance (KFLC: 7±5.3 mg/L vs. 5±2.3 mg/L, p= 0.11; LFLC: 0.7±0.33 mg/L vs. 0.5±0.23 mg/L p=0.16). A strong inverse correlation was observed between the concentration of K and LFLCs at diagnosis and the change in PBVC during follow-up (r= - 0.72 and r= - 0.65, respectively).
Conclusion: FLC concentrations at CIS diagnosis were not significantly higher in CIS-converters compared to CIS non-converters, but patients with higher CSF FLC concentrations tended to have increased brain atrophy during follow-up.
Disclosure: No funding